Overall Survival Benefit With Durvalumab Continues at 3-Year Follow-Up
Patients with advanced non-small cell lung cancer who did not have disease progression after chemoradiotherapy appeared to have a long-term survival benefit with durvalumab.
Non-Small Cell Lung Cancer
Characteristics Identified for Checkpoint Inhibitor-Resistant Patients
Patients with NSCLC who did not respond to immune checkpoint blockade had unique molecular characteristics, revealing possible therapeutic targets.
No PRO Detriments Observed With Durvalumab for Stage III Unresectable NSCLC Compared With Placebo
No significant differences in PROs were observed among patients treated with subsequent durvalumab after chemoradiation therapy for stage III unresectable NSCLC compared with those who received subsequent placebo.
Ceritinib Plus Nivolumab in NSCLC Characterized by an ALK Mutation
Among patients who were naive to ALK inhibition, the overall response rate was 83% for the 450-mg dose and 60% for the 300-mg dose.
Genomic Assay Shows Utility in Selecting NSCLC Patients for Targeted Therapy
Next-generation sequencing of circulating tumor DNA (ctDNA) may identify patients who are likely to benefit from targeted therapy for NSCLC.
EGFR-Positive Lung Cancer Diagnosis and Patient Quality of Life
Cost of therapy was a major concern among a majority (69%) of patients with lung cancer who responded to the survey.
Risk Model Predicts Survival in NSCLC Patients Treated with Immunotherapy
Researchers identified and validated novel risk groups models that predict OS and PFS among NSCLC patients treated with immunotherapy.
Capmatinib Treats Brain Metastases in NSCLC With MET Exon-14 Skipping Mutation
Researchers observed 4 patients whose brain lesions were completely resolved by treatment with capmatinib.
AMG 510 Well Tolerated by Patients With NSCLC
A phase 1 trial found that AMG 510 is tolerated in patients with previously treated non-small cell lung cancer.
Circulating Autoantibodies Could Predict Patient Response to Immunotherapy
Researchers found that IMP2, a cancer autoantibody, was significantly associated with time to progression in patients with NSCLC treatment with non-frontline PD-1/PD-L1.
Next post in IASLC North America 2019
